Moxifloxacin is a novel fourth generation fluoroquinolone antibacterial drug effective in the treatment of bacterial conjunctivitis. Ocuserts containing different combination of HPMC (E-50), EC and PVP (K-30). The ocuserts were prepared by solvent casting technique and characteristic like thickness, weight variation, drug content, moisture loss, moisture absorption, ocular irritation study, in vitro release sterility test and microbiological studies. All the ocuserts were found to be sterile, non irritant and stable. The drug content of the ocusert was found to be varied between 96.00 - 97.90 %. All the formulations followed zero order release pattern. Ocusert (MHF 4) containing EC (600 mg) and HPMC (400 mg) has shown good in vitro controlled release i.e. 77.13% was found to be better than the other formulations over an extended period of 8 hours and showed excellent microbiological activity for 3 days and remained stable and intact at ambient conditions.
Loading....